2016-01-07

Camurus's initial public offering a success

On Thursday December 3, 2015, Camurus started its first day of trading on Nasdaq Stockholm. The share price increased considerably during the first day and Camurus is now the largest company in the biotechnology sector on Nasdaq Stockholm

The price of the Camurus share was set at SEK 57, but at closing time the share was noted at SEK 65,5, an increase of no less than 15,7 percent. The upturn meant that the market capitalization of Camurus was close to SEK 2,5 million at the end of the day. Today (January 2016) the market capitalization is about SEK 2,8 million.

Sandberg Development will remain the largest shareholder in Camurus and will hold appr. 54 percent of the total number of shares in the company.

Latest news

2020-07-16

Camurus' Interim Report Second Quarter 2020

”For the fourth quarter in a row, we saw Buvidal® sales growth of more than 50%”

Read more

2020-06-24

Positive results from Phase 2 study

Positive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers…

Read more

2020-06-23

Camurus raises full year 2020 revenue guidance

The improvements are driven by increasing market shares of Buvidal® for treatment of opioid dependence in Europe and…

Read more

2020-05-07

Camurus Interim Report January-March 2020

”The number of patients treated with Buvidal® increased by 90 percent in the quarter”

Read more

2020-04-08

Camurus Annual Report for 2019

Camurus Annual Report for 2019 is now available at the company´s website.

Read more